Abstract:Purpose Dopamine transporter (DAT) is a promising target for positron emission tomography (PET) imaging of many neuropsychiatric diseases. 18 F-labelled N-alkyl tropane analogues were reported to be useful PET radioligands for DAT. However, the drawback of 18 F-labelled tropane analogues is that N -alkyl on tropane is easily metabolized in vivo , which interferes with brain imaging. To develop a more in vivo stable DAT-targeted PET radioligand with high DAT affinity and specificity, in this study, we synthesized and compared a series of 18 F-labelled novel deuterated N-fluoropropyl tropane derivatives [ 18 F] 4a-e for DAT tracing. Procedures Five deuterated N-fluoropropyl-d 6 tropane derivatives ( 4a-e ) and corresponding non-deuterated compounds ( 6a-e ) were synthesized, and their semi-inhibitory concentrations (IC 50 ) were measured by competitive binding assay. The radioligands [ 18 F] 4a-e and [ 18 F] 6a-e were obtained by two-step one-pot radio-labelling reactions. The selectivity and specificity of these radioligands were evaluated by cellular uptake and microPET in normal rats. [ 18 F] 4e was selected for further investigation with microPET of the PD model, autoradiography and biodistribution experiments and compared with its non-deuterated [ 18 F] 6e . Finally, in vivo metabolic stability was analyzed by radio-HPLC. Results Ten tropane compounds had high DAT affinity (IC 50 = 2–21 nM), in which FP-CIT-d 6 ( 4e ) had the lowest IC 50 value of 2.7 nM. Radiolabelled [ 18 F] 4a-e and [ 18 F] 6a-e were obtained with radiochemical yields ranging from 10.6 ± 2.8% to 35.1 ± 5.4% with molar activities >20 GBq/μmol and the radiochemical purities >99%. [ 18 F] 4e showed the highest cell uptake (12%) and CFT inhibition efficacy (∼72%) among [ 18 F] 4a-e . MicroPET results showed [ 18 F] 4e has the highest target to non-target ratio (striatum/cerebellum). Therefore, [ 18 F] 4e was then selected for further biological evaluation. Ex vivo autoradiography experiment confirmed high specific binding of [ 18 F] 4e towards DAT. Biodistribution results indicated that [ 18 F] 4e has a higher striatum/cerebellum value than [ 18 F]FP-CIT ([ 18 F] 6e ) at 30–120 min. Furthermore, in vivo metabolism studies in rats revealed improved stability of [ 18 F] 4e as compared with that of [ 18 F] 6e . Conclusions The new probe [ 18 F] 4e is a promising candidate with good DAT affinity, specificity and metabolic stability for PET imaging, and might provide reliable diagnosis, treatment and prognostic detection of DAT-related neuropsychiatric diseases.

18F-Labelled pyrrolopyrimidines reveal brain leucine-rich repeat kinase 2 expression implicated in Parkinson’s disease

Preclinical Evaluation of Novel Positron Emission Tomography (PET) Probes for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2)

Radiosynthesis and Evaluation of 4-(6-[18f]fluoro-4-(5-isopropoxy-1h-indazol-3-yl)pyridin-2-yl)morpholine As a Novel Radiotracer Candidate Targeting Leucine-Rich Repeat Kinase 2.

Changes of Dopamine Transporter Detected by 11C-CFT PET in LRRK2-knockoutand G2019 Transgenicmice

[A study of microPET for assessing regional cerebral glucose metabolism and the expression of dopamine receptor type 2 in a rat model of Parkinson's disease].

Development of Pyridothiophene Compounds for PET Imaging of α‐Synuclein

Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson’s Disease

Evaluation of the early response and mechanism of treatment of Parkinson's disease with L-dopa using 18F-fallypride micro-positron emission tomography scanning

Leucine-rich repeat kinase 2 (LRRK2) inhibition upregulates microtubule-associated protein 1B to ameliorate lysosomal dysfunction and parkinsonism

GTP‐binding inhibitors increase LRRK2‐linked ubiquitination and Lewy body‐like inclusions

Discovery of potent LRRK2 inhibitors by ensemble virtual screening strategy and bioactivity evaluation

Design, Synthesis and Identification of N, N-dibenzylcinnamamide (DBC) Derivatives As Novel Ligands for Α-Synuclein Fibrils by SPR Evaluation System.

Imaging Striatal Microglial Activation in Patients with Parkinson’s Disease

Comparison of 18F-DOPA and 18F-DTBZ for PET/CT Imaging of Idiopathic Parkinson Disease

Synthesis and biological evaluation of 18 F-labelled deuterated tropane derivatives as dopamine transporter probes

Advances in the Use of Positronic Radiomolecular Imaging Agents in the Diagnosis of Parkinson's Disease

Radiosynthesis and Preclinical Evaluation of [18F]F-DPA, A Novel Pyrazolo[1,5a]pyrimidine Acetamide TSPO Radioligand, in Healthy Sprague Dawley Rats

Exploring [ C]CPPC as a CSF1R-targeted PET Imaging Marker for Early Parkinson’s Disease Severity

In Vivo Detection of Monoaminergic Degeneration in Lipopolysaccharide-Induced Rat Model of Parkinson's Disease Using 18F-FP-(+)-DTBZ (18F-AV-133) PET

Exploration of Fluorinated Pyrazolidine-3,5-diones for Positron Emission Tomography Imaging of the P2Y12 Receptor in the Central Nervous System

Comparison of 18F-DOPA and 18F-DTBZ for PET/CT Imaging of Idiopathic Parkinson’s Disease